Washington University School of Medicine Researcher Updates Knowledge of Non-Small Cell Lung Cancer [Phase I/II study of pegylated arginine deiminase (ADI-PEG 20) in combination with gemcitabine and docetaxel in non-small cell and small cell...].

A recent study conducted by researchers at Washington University School of Medicine in St. Louis has explored the use of pegylated arginine deiminase (ADI-PEG 20) in combination with gemcitabine and docetaxel for the treatment of non-small cell lung cancer (NSCLC) and small-cell lung cancer (SCLC). The study found that ADI-PEG 20, when combined with gemcitabine and docetaxel, showed increased expression of hENT, a transporter for gemcitabine, as well as upregulation of dCK to trap gemcitabine inside cancer cells. The phase I portion of the trial is nearing completion, and the phase II portion will evaluate the objective response rate (ORR) in separate cohorts for NSCLC and SCLC. [Extracted from the article]